2021 ASCO Virtual Annual Meeting*

Download All
June 4-8, 2021; Online at https://conferences.asco.org/am
Expert faculty review and share their insights and perspectives on key findings in hematologic malignancies presented at the 2021 ASCO Annual Meeting.
Ian W. Flinn, MD, PhD
Shaji K. Kumar, MD
Eunice S. Wang, MD

Hematologic Malignancies

Slidesets OPTIC: A Phase II Dose-Optimization Trial Evaluating 3 Different Starting Doses of Ponatinib in CP-CML
Slidesets ZUMA-3: Phase II Results With Brexucabtagene Autoleucel for Relapsed/Refractory Adult B-Cell ALL
Slidesets Phase II Study of IDH2 Inhibitor Enasidenib in Patients With High-Risk IDH2-Mutated MDS
Slidesets Venetoclax + Azacitidine vs Azacitidine Monotherapy in Chemotherapy-Ineligible Patients With tAML or AML From Antecedent MDS or CMML
Slidesets Phase Ib/II Trial of Ivosidenib + Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies
Slidesets QUAZAR AML-001 Multivariate Analysis: Predictors of Survival Outcomes With Oral Azacitidine (CC-486) Among Patients With AML in Remission After Intensive Chemotherapy
Slidesets MRD Response and Prognosis With Venetoclax + Azacitidine in Patients With AML Ineligible for Intensive Induction Chemotherapy From the VIALE-A Trial
Slidesets ELEVATE-RR: Acalabrutinib vs Ibrutinib in Previously Treated CLL
Slidesets CAPTIVATE: Primary Analysis From the Fixed-Duration Cohort of First-line Ibrutinib + Venetoclax for CLL/SLL
Slidesets Phase Ib Trial of Venetoclax, Lenalidomide, and Rituximab in Untreated Mantle Cell Lymphoma
Slidesets ELARA: Efficacy and Safety of Tisagenlecleucel in Relapsed/Refractory Follicular Lymphoma
Slidesets ELEVATE-TN: 4-Year Follow-up Analysis of Acalabrutinib ± Obinutuzumab vs Obinutuzumab + Chlorambucil for Treatment-Naive CLL
Slidesets EPCORE NHL-1: Update From First-in-Human Phase I/II Trial of Epcoritamab, an Anti-CD3/Anti-CD20 Bispecific Antibody, in R/R B-Cell NHL
Slidesets FORTE Subanalysis: Efficacy of KRd With or Without ASCT Followed by KR or R Maintenance in Patients With ND MM According to Cytogenetic Risk Status
Slidesets CASSIOPEIA Part 2: Daratumumab Maintenance or Observation After Treatment With VTd or D-VTd and ASCT in Newly Diagnosed MM
Slidesets MagnetisMM-1: Efficacy, Safety, and Tolerability of Subcutaneous Elranatamab in Patients With Relapsed/Refractory Multiple Myeloma
Slidesets Updated Findings From the Phase II KarMMa Study of Idecabtagene Vicleucel for R/R Multiple Myeloma
Slidesets ICARIA-MM: Second Interim Analysis of Phase III Study of Addition of Isatuximab to Pomalidomide and Low-Dose Dexamethasone in R/R Myeloma
Slidesets Randomized Phase II Trial of Ixazomib + Dexamethasone vs Pomalidomide + Dexamethasone in Relapsed/Refractory Multiple Myeloma
Slidesets IKEMA Subgroup Analyses: Isatuximab Plus Carfilzomib/Dex vs Carfilzomib/Dex in Patients With Relapsed/Refractory MM
Slidesets DREAMM-2: Exploration of BCVA, Ocular Symptoms, and OSDI Questionnaire as Surrogates for Corneal Alterations During Treatment With Belantamab Mafodotin in R/R MM

In this expert analysis, Ian W. Flinn, MD, PhD; Shaji Kumar, MD; and Eunice S. Wang, MD, discuss clinically relevant data on hematologic malignancies presented at ASCO 2021.

Ian W. Flinn, MD, PhD Shaji K. Kumar, MD Eunice S. Wang, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits™ Released: September 13, 2021 Expired: No longer available for credit
Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
AstraZeneca
Bristol-Myers Squibb
GlaxoSmithKline
Novartis Pharmaceuticals Corporation
Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.
Sanofi Genzyme

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings